Teddy European Network of Excellence for Paediatric Research was funded in 2005 with the aim to favor the integration of the paediatric pharmacological research activities and contribute to the promotion of safe and efficacious medicines for children.
TEDDY is a Network of Excellence (NoE), strongly proactive in the promotion and implementation of adequate health policies and a social awareness on the importance of the paediatric medicines across Europe.
Today, TEDDY is an independent multidisciplinary, multinational Network composed of partners from more than 20 countries aimed at facilitating the performance of good quality paediatric studies and research.
TEDDY is a category 1 network member of Enpr-EMA, the European Network of Paediatric Research at the European Medicines Agency.
Moreover, TEDDY is member of Enpr-EMA Coordinating Group.
EMA consultation: ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – Q&A
The European Medicines Agency has published for public consultation the ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - questions & answers.
EPTRI (European Paediatric Translational Research Infrastructure), the European project funded within H2020 Infradev-01-2017 call for proposals and coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) reached the end of its exciting journey,